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a b s t r a c t
Multidrug resistance (MDR), which is the main obstacle to cancer chemotherapy, is mainly due to
overexpression of ATP-binding cassette (ABC) transporters, especially ABCB1 (P-glycoprotein), ABCC1
(MRP1), and ABCG2 (BCRP). A novel idea to overcome MDR is that of collateral sensitivity, i.e., ﬁnding
a treatment to which cells overexpressing ABC transporters are more sensitive than cells that do not
overexpress them. In this study we demonstrate for the ﬁrst time that MDCKII-BCRP cells, over-
expressing ABCG2, are more vulnerable to exogenous oxidative stress induced by several oxidants, viz.
paraquat, menadione, hydrogen peroxide, tert-butylperoxide, and 2,2-azobis(2-methylpropionamidine)
dihydrochloride. MDCKII-BCRP cells have signiﬁcantly decreased glutathione level and decreased
activities of glutathione S-transferase and glutathione reductase, which may underlie their augmented
vulnerability to oxidative stress. These results suggest the possibility of using agents that induce
oxidative stress to selectively kill cells overexpressing BCRP.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
For many years chemotherapy has been the most common
mode of treatment for metastatic and hematological tumors.
Unfortunately, the use of anticancer drugs leads to overexpression
of ABC transporters and development of resistance to these agents.
Some cancers such as rectal, lung, and non-small-cell cancers
show so-called neutral or primal resistance in that they do not
respond to standard chemotherapy drugs. Overexpression of ATP-
binding cassette (ABC) transporters is the main reason for multi-
drug resistance (MDR). These proteins function as efﬂux pumps
actively transporting drugs out of the cells against concentration
gradients by ATP hydrolysis. The resulting decrease in the intra-
cellular drug concentration makes chemotherapy ineffective.
Because these proteins have a very broad speciﬁcity, drug resis-
tance conferred by them covers many drugs and is referred to as
MDR [1–4].
ATP-binding cassette transporters are present in all living
organisms, from bacteria to humans, and they are among the
largest and most widely expressed protein superfamilies known.
In humans, 49 ABC genes have been described and organized into
seven subfamilies (A–G), and consistent nomenclature, mainly
based on sequence homology, has been adopted [5–7]. Their
structure contains a conserved ATP-binding cassette and a trans-
membrane domain (TMD) [8]. An ABC protein may contain two
ATP-binding cassettes and two TMDs (full transporters) or one
ATP-binding cassette and one TMD (so-called half-transporters,
which must dimerize to become functional) [8]. The polypeptide
chain, which threads multiple times through the membrane,
typically forms six transmembrane α-helices. For most transpor-
ters, getting their substrate across a membrane requires energy,
which is provided by binding and subsequent hydrolysis of ATP
at their nucleotide-binding domains (NBDs) [6,7]. There are two
sequence motifs situated 100–200 amino acids apart in each NBD
—Walker A (the lysine residues in this motif are involved in the
binding of ATP) and Walker B (the aspartic acid residues in this
motif interact with Mg2þ)—and additionally a signature C motif
unique to the ABC superfamily [9–11]. It is believed that the
conformational changes within domains are responsible for the
transport of substrates across membranes [11].
Apart from the fact that the multidrug transporter ABC proteins
cause chemotherapy resistance in cancer, these proteins play an
important role as export pumps of endogenous compounds and
exogenous toxic agents in a variety of cells and tissues, especially in
the blood–brain barrier (BBB) [4,12]. The BBB is a barrier that
separates circulating blood from the brain extracellular ﬂuid in the
central nervous system [13]. It is formed along brain microvessels
and consists of tight junctions with endothelial cells around capil-
laries and as a result regulates passage of substances into and out of
the central nervous system [8,13]. The ABC transporters breast cancer
resistance protein (BCRP, ABCG2) and P-glycoprotein (ABCB1) show
high expression at the BBB [14]. Both are situated in the luminal
plasma membranes of the brain capillary endothelial cells and, as
mentioned, play a physiologically protective role [12,14].
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There are three major ABC proteins involved in cancer multi-
drug resistance: P-glycoprotein (MDR1, ABCC1), BCRP, and
multidrug resistance protein 1 (MRP1, ABCC1) [2,15]. All these
proteins can transport a large variety of hydrophobic drugs, drug
conjugates, or anionic drugs, their speciﬁcities overlapping to a
considerable extent.
The ABCG2 transporter (known also as BCRP or mitoxantrone
resistance protein, MXR) is a plasma membrane hemitransporter
of 72 kDa composed of 665 amino acids, containing only one NBD
followed by one membrane-spanning domain [15–17]. It also
excretes endogenous metabolites or physiological substrates [15].
Physiologically, ABCG2 is highly expressed in areas such as the
blood–brain barrier and gastrointestinal tract, where it is thought
to play a role in protection against xenobiotic exposure. However,
ABCG2 is also involved in multidrug resistance because it is a
broad-speciﬁcity transporter that appears to export both nega-
tively and positively charged drugs including anticancer agents
(mitoxantrone, topotecan, methotrexate) and antibiotics (cimeti-
dine, prazocin, ﬂuoroquinolone), phototoxins, heme/porphyrin,
and sulfate conjugates. It has been postulated that the list of
ABCG2 substrates includes glutathione, i.e., that ABCG2 transports
glutathione out of the cell [18,19].
Glutathione (GSH) is one of the most essential intracellular
nonenzymatic antioxidants and is maintained at millimolar con-
centrations within the cells [19,20]. GSH plays an important role in
cell physiology both in the normal state (cell proliferation, apop-
tosis, immune response) and in disease (cancer, liver diseases,
Parkinson disease) [21]. Cells express membrane proteins capable
of transporting GSH, glutathione disulﬁde (GSSG), and GSH con-
jugates [21]. Currently there are only a few ABC transporters
known to be capable of transporting GSH and glutathione con-
jugates across the membrane. The main role in this respect is
played by the ATP-binding-cassette C (ABCC) subfamily: ABCC1,
ABCC2, ABCC3, ABCC4, ABCC5, and ABCC7 [22,23].
GSH export by ABCG2 may create new opportunities for antic-
ancer therapy. Active GSH efﬂux from cells overexpressing ABCG2,
and thus lower intracellular GSH levels, may cause increased
sensitivity of these cells to oxidative stress. The aim of this
study was to examine the effects of ABCG2 overexpression
on the glutathione levels and sensitivity to oxidative stress of
MDCKII cells.
Materials and methods
Reagents
Cell culture media, phosphate-buffered saline (PBS), and fetal
bovine serum were from Gibco (Life Technologies). Fluoro-
genic dyes were from Molecular Probes (Life Technologies). All
other reagents were purchased from Sigma–Aldrich unless stated
otherwise.
Cell cultures
MDCKII and MDCKII-BCRP cells were obtained from Solvo
Biotechnology. Cells were cultured in 75-cm2 cell culture ﬂasks
(Nunc) in Dulbecco's modiﬁed Eagle mediumwith 10% fetal bovine
serum at 37 1C in a humidiﬁed-air atmosphere containing 5%
carbon dioxide. Cells were passaged when the cultures reached
70–85% conﬂuence. The cells were trypsinized, counted by the
Countess automated cell counter (Invitrogen), and plated at
4104 cells/cm2 in a new ﬂask or used for experiments.
Cytotoxicity assay
Cytotoxicity was estimated using two assays: the resazurin
assay and the neutral red assay. Brieﬂy, in the resazurin assay
15103 MDCKII and MDCKII-BCRP cells per well were plated in
96-well black tissue culture plates and after 24 h were exposed
to the chosen oxidants in Dulbecco's modiﬁed Eagle medium
(DMEM) with 10% fetal bovine serum at 37 1C. After 24 h incuba-
tion the cells were rinsed with PBS and incubated at 37 1C in a
humidiﬁed-air atmosphere containing 5% CO2 with 4 mM resazurin
in Hanks’ buffered salt solution (HBSS) for 2 h. Cytotoxicity was
measured as decreased reduction of resazurin to its ﬂuorescent
product resoruﬁn. Fluorescence was measured using an excitation
wavelength of 560 nm and emission wavelength of 590 nm.
The neutral red assay is based on the ability of viable cells to
incorporate and bind the supravital dye neutral red in the lyso-
somes (reductant-independent assay). Brieﬂy, 15103 MDCKII
and MDCKII-BCRP cells per well were seeded in 96-well tissue
culture plates and after 24 h were treated with oxidants for next
24 h. Then the cells were rinsed with PBS and incubated at 37 1C in
a 95% moist atmosphere with 5% carbon dioxide in DMEM
containing 50 mg/ml neutral red. The cells were subsequently
washed with PBS and the dye was extracted in each well using
50% ethanol with 1% acetic acid in distilled water. Then the plates
were shaken in a Thermomixer Comfort (Eppendorf) for 10 min
and absorbance was measured using an EnVision multilabel reader
(PerkinElmer) at 540 nm.
When ABCG2 inhibitors were used, they were present in the
medium together with the oxidants (24 h).
Analysis of the level of gene expression
Total RNA was isolated from 1 million MDCKII or MDCKII-BCRP
cells employing a MagNA Pure LC 2.0 Instrument (Roche) accord-
ing to the manufacturer's protocol. After genomic DNA removal by
RNase-free, DNase I digestion, total RNA of 1 mg was reverse-
transcribed using the SuperScript III First-Strand Synthesis Super-
Mix (Life Technologies). PCR analysis was performed on a C1000
thermal cycler–CFX96 real-time system (Bio-Rad). The following
abcb1, abcc1, abcg2, and hnrnph1 primers were used: ABCB1-R,
50-GTTGCAGGCCTCCGTTTAT-30; ABCB1-F, 50-TGAGAATGTACCTCCA-
GTTTCC-30; ABCC1-R, 50-AGAGTCACAGTACACGGCCC-30; ABCC1-F,
50-GACAGAGATTGGTGAGAAGGG-30; ABCG2-R, 50-GATGACACTCTG-
TAGTATCCACTGAT-30; ABCG2-R, 50-TCAGCAGTGTGTCAGCTGTG-30;
and HNRNPH1-R, 50-TAGCCTCCATAACCTCCAC-30; HNRNPH1-F,
50-CTCACTATGATCCACCACG-30. mRNA expression was analyzed
using the iQ SYBR Green Supermix (Bio-Rad). After 3 min of an
initial activation and denaturation step at 95 1C, 40 cycles were per-
formed including a denaturation step at 95 1C for 15 s and annealing/
extension step at 60 1C for 45 s, followed by a melt-curve analysis
(55–95 1C, 0.5 1C increment, 5 s/step). DNA was omitted in the
nontemplate control. Amounts of cDNA were normalized to the
housekeeping gene, hnrnph1, using the ΔCt method.
Protein concentration assay
All results were converted into protein concentration using the
Pierce 660 nm Protein Assay Reagent (Thermo Scientiﬁc). The
assays were optimized for MDCKII cells. MDCKII and MDCKII-
BCRP cells (2104 per well) were seeded on a 96-well plate in
100 ml DMEM with 10% fetal bovine serum. After 24 h of culture,
the medium was removed, cells were washed with 200 ml of PBS,
and 50 ml distilled water was added to each well and then the
plates were frozen at 20 1C overnight and thawed multiple times
to lyse the cells. Then 150 ml of Pierce Protein Reagent was added
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to 20 ml of cell lysate and mixed well, and the plates were
incubated at room temperature for 10 min. Finally, absorbance
were measured using 660-nm wavelength and protein concentra-
tion was determined from the BCA protein standard curve.
Glutathione reductase activity
Glutathione reductase was assayed on the basis of NADPH
oxidation [24]. Brieﬂy, 50 ml of cell lysate and 100 ml of 200 mM
NADPH in phosphate buffer (100 mM, pH 7.5, with 1 mM EDTA)
were added to each well and mixed gently. Then 50 ml of 4 mM
GSSG in phosphate buffer (prepared fresh before use) was added
to each well and mixed gently and the absorbance was followed at
340 nm for 5 min. The reaction was carried out at 37 1C.
Glutathione peroxidase activity
Glutathione peroxidase activity was measured in a coupled
assay with glutathione reductase by monitoring NADPH oxidation
[25]. Brieﬂy, 50 ml of 100 mM phosphate buffer, pH 7.0, containing
0.1 mM EDTA and 2 mM sodium azide, 10 ml of cell lysate, 10 ml of
glutathione reductase (2.4 U/ml), 10 ml of 10 mM GSH (prepared
fresh before use), and 10 ml of 1.5 mM NADPH in 0.1% sodium
bicarbonate were added to each well and mixed gently. Reaction
was initiated with 10 ml of 1.5 mM hydrogen peroxide and absor-
bance was monitored at 340 nm. Simultaneously, a blank sample,
containing 10 ml of distilled water instead of cell lysate, was
measured. The measurements were run at 37 1C for 10 min.
Glutathione S-transferase activity
Glutathione S-transferase activity was measured with 1-chloro-
2,4-dinitrobenzene (CDNB) [26]. Brieﬂy, 160 ml of 0.1 M phosphate
buffer, pH 6.5, 10 ml of 20 mM GSH (freshly prepared in water), and
10 ml of 20 mM CDNB in methanol were added to each well of a
96-well plate and mixed properly. Finally, 20 ml of cell lysate was
added. Simultaneously, a blank sample was prepared (180 ml of
phosphate buffer, 10 ml of GSH, and 10 ml of CDNB). Absorbance
was monitored at 340 nm at 30 1C, for 10 min.
GSH content
The content of reduced glutathione was assayed with ortho-
phthalaldehyde (OPA) [27]. Two black 96-well plates were pre-
pared: “þ” and “”. To each well of both plates 25 ml of cell lysate
was added, and then 4 ml of redox quenching buffer (RQB) with
7.5 mM N-ethylmaleimide (RQB buffer: 20 mM HCl, 5 mM diethy-
lenetriaminepentaacetic acid, 10 mM ascorbic acid) was added to
the “” plate. Afterward 40 ml of KPi1 buffer (1 M phosphoric acid
adjusted to pH 7 with KOH) was added to each plate, mixed gently,
and incubated 5 min at room temperature. Then 160 and 156 ml of
KPi0.1 (KPi1 diluted 10-fold) were respectively added to the “þ”
and “” plates. Finally 25 ml of OPA solution (0.5% in methanol)
was added to each well in both plates and incubated 30 min with
gentle stirring. Fluorescence was measured using an extinction
wavelength of 355 nm and emission wavelength of 430 nm. GSH
concentration was determined by subtracting the ﬂuorescence
of the “” plate from the ﬂuorescence of the “þ” plate and
calculated in relation to the protein content.
All the spectrophotometric and spectroﬂuorimetric measure-
ments were done in an EnVision multilabel plate reader
(PerkinElmer).
Reactive oxygen species (ROS) level
The levels of reactive oxygen and nitrogen species were estimated
with ﬂow cytometry using an LSRII apparatus (BD Biosciences)
according to the Molecular Probes protocols. Six ﬂuorogenic dyes
were used: 20,70-dichlorodihydroﬂuorescein diacetate (H2DCFDA),
dihydrorhodamine 123 (DHR123), MitoSOX, Amplex red, 4-amino-
5-methylamino-20,70-diﬂuoroﬂuorescein diacetate (DAF-FM), and
dihydroethidium (DHE).
Brieﬂy, MDCKII and MDCKII-BCRP cells were incubated at 37 1C
for 15 min with 1 mM Amplex red, 1 mM MitoSOX, 5 mM H2DCFDA,
1 mM DHR123, or 1 mM DHE and the ﬂuorescence of the products
was measured. Reactive nitrogen species were estimated using
DAF-FM. Brieﬂy, 1 and 10 mM DAF-FM was added to MDCKII and
MDCKII-BCRP cells and mixed well and the changes in ﬂuor-
escence were measured every 5 min for 20 min and then every
15 min for 90 min.
Statistical analysis
Statistical t-test analyses were performed using the GraphPad
Prism5 software with p o 0.05 considered signiﬁcant.
Results
The level of expression of the abcg2 gene in MDCKII-BCRP cells,
estimated by qPCR, was 178,727.6 copies per 106 copies of the
housekeeping gene (HNRNPH1), whereas in control cells it
was 1.6 copies. Overexpression of abcg2 was not accompanied by
signiﬁcant overexpression of genes coding for any other main
ABC protein: the level of expression of abcb1 was 16.6 copies in
MDCKII and 12.8 copies in MDCKII-BCRP, whereas that of abcc1
was 29.8 and 31.0 copies, respectively, per 103 copies of the
housekeeping gene.
The elevated expression level of abcg2 in MDCKII-BCRP cells
was also conﬁrmed at the protein level using BXP-21 (Abcam)
antibodies. The levels of ABCC1 and ABCB1 were not signiﬁcantly
increased in MDCKII-BCRP cells as estimated with MRPr1 and F4
antibodies (Abcam), respectively (not shown).
MDCKII cells overexpressing BCRP were more sensitive than
control cells to hydrogen peroxide and ROS-generating agents:
paraquat, menadione, and tert-butylhydroperoxide (tBOOH), when
estimated with the resazurin test. They were also more sensitive to
2,2-azobis(2-methylpropionamidine) dihydrochloride (AAPH) in
the concentration range of 50 mM–5 mM although the IC50 for
this compound could not be determined from the data (Fig. 1).
However, cell sensitivity to diamide was not altered (not shown).
As the resazurin test is redox-sensitive, the neutral red test was
also used to conﬁrm the differences between both cell lines. The
results, though yielding different values of IC50, were similar in
showing the increased sensitivity of ABCG2-overexpressing cells to
oxidants (Table 1).
Treatment with the ABCG2 inhibitor Ko143 ((3S,6S,12aS)-1,2,
3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-diox-
opyrazino[10,20:1,6]pyrido[3,4–b]indole-3-propanoic acid 1,1-
dimethylethyl ester) [28] did not affect the survival of either control
or ABCG2-overexpressing cells, indicating that the increased sensi-
tivity of the latter is not directly due to the transport function of the
protein inhibitable by Ko143.
The increased sensitivity to oxidants of ABCG2-overexpressing
cells may be due to impaired antioxidant defense or oxidative
stress, which could affect the sensitivity to exogenous oxidants.
The content of glutathione was 113.8718.8 nmol/mg protein in
control and 71.875.3 nmol/mg protein in ABCG2-transfected
MDCKII cells. Glutathione S-transferase and glutathione reductase
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activities were decreased in ABCG2-transfected cells (0.1070.04
vs 0.2070.07 U/mg protein, 0.5170.13 vs 0.5970.20 U/mg pro-
tein, respectively), but glutathione peroxidase was unchanged
(Table 2). These results point to impairment of antioxidant defense
in cells overexpressing ABCG2. Interestingly, the action of Ko143
did not affect signiﬁcantly the content of glutathione in control or
ABCG2-overexpressing cells either in the absence of exogenous
oxidant or in the presence of 150 and 200 mM hydrogen peroxide
(not shown).
To further characterize the role of ABCG2 overexpression in
the redox balance of the cells, we compared the generation
of ROS and reactive nitrogen species in the cells using ﬂuorescent
probes: H2DCFDA, DHR123, MitoSOX, Amplex red, and DAF-FM.
DHR123 is an uncharged and nonﬂuorescent product, which
passively diffuses across most cell membranes where it is oxidized
to cationic rhodamine 123, which itself localizes in the mitochon-
dria. H2DCFDA is also nonﬂuorescent and, upon cleavage of the
acetate groups by intracellular esterases and subsequent oxidation,
is converted into the highly ﬂuorescent 20,70-dichloroﬂuorescein.
Both probes react with various reactive species, including hydro-
gen peroxide but not superoxide or nitric oxide [29]. Amplex red is
used as a detector of the release of H2O2, and in the presence of
Fig. 1. Viability of MDCKII (■) and MDCKII-BCRP cells (○) treated with various oxidants for 24 h. The cells were exposed to the chosen oxidants in DMEM with 10% fetal
bovine serum at 37 1C. After 24 h incubation the cells were rinsed with PBS and incubated at 37 1C in a humidiﬁed-air atmosphere containing 5% CO2 with 4 mM resazurin in
HBSS for 2 h. Cytotoxicity was measured as decreased reduction of resazurin to its ﬂuorescent product resoruﬁn and expressed as a percentage of that of control cells (not
treated with any oxidant).
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peroxidase it reacts with H2O2 in a 1:1 stoichiometry and produces
highly ﬂuorescent resoruﬁn [29]. MitoSOX red is a cationic
compound reacting mainly with mitochondrially derived super-
oxide [29]. We found that the level of ROS estimated with DHR123,
MitoSOX, and Amplex red (Fig. 2) was higher for ABCG2-
transfected than for control cells. The increased oxidation of
MitoSOX red, reacting mainly with mitochondria-derived super-
oxide in the transfected cells, and the lack of differences in the
oxidation of dihydroethidine reacting with cytosolic superoxide
suggest that mitochondria are the main source of ROS in the
MDCKII-BCRP cells, apparently owing to intensiﬁed respiration.
Discussion
Currently chemotherapy is one of the basic methods for
combating metastatic and hematological malignancies. Unfortu-
nately, multidrug resistance is a signiﬁcant complication of che-
motherapy and as yet no successful treatment has been developed
to combat it. Intense research is therefore concentrated on ﬁnding
inhibitors of multidrug transporters, which are the main cause of
the multidrug resistance, and alternative ways to overcome multi-
drug resistance.
An ingenious idea formulated in this respect is that of collateral
sensitivity. Overexpression of a multidrug transporter must be a
burden for a cell and changes its physiology. If so, it is hoped that
an Achilles heel can be found, which can make a resistant cell
more vulnerable to the action of some agents [1]. For example,
increased export activity can lead to ATP depletion or oxidative
stress owing to intensiﬁed oxidative phosphorylation necessary to
maintain the ATP level [3]. Another drawback of overexpression of
ABCG2 may be a decreased level of the main intracellular anti-
oxidant, glutathione [18], which could enhance the sensitivity to
oxidative stress.
We found decreased levels of glutathione in MDCKII cells
overexpressing ABCG2 (Table 2). Our results conﬁrm the data of
other authors, suggesting that export of GSH by ABCG2 is a general
phenomenon. Brechbuhl et al. [18] measured extracellular GSH
levels in HN4 and MDA1586 cells, both derived from head and
neck cancers. They overexpressed ABCG2 2-fold in HN4 cells
compared to the parental line and showed a 2.5-fold increase in
basal extracellular GSH levels, apparently due to export by ABCG2.
They also suppressed ABCG2 in MDA1586 cells transfected with
ABCG2 shRNA, resulting in a 2.6-fold decrease in ABCG2 protein
expression, correlating to a 2.7-fold decrease in basal extracellular
GSH levels [18]. Gauthier et al. [30] reported decreased
Table 1
IC50 values of control MDCKII cells and MDCKII cells overexpressing ABCG2 (MDCKII-BCRP) for chosen oxidants, estimated using the resazurin assay and the neutral
red assay.
Oxidant MDCKII (mM) MDCKII-BCRP (mM)
Resazurin assay
H2O2 232.2 (188.0–291.4) 119.0 (91.3–155.1)
tBOOH 184.2 (119.8–283.1) 28.6 (24.1–34.1)
Menadione 101.0 (71.2–143.2) 37.6 (32.1–44.0)
K2Cr2O7 17.6 (12.7–24.3) 4.2 (3.6–4.9)
MDCKII MDCKII-BCRP
No inhibitor 10 mM Ko143 No inhibitor 10 mM Ko143
Neutral red assay
H2O2 195.0 (192.2–197.7) 195.2 (192.5–197.8) 118.7 (114.0–123.7) 119.2 (114.9–123.5)
tBOOH 79.1 (77.5–80.7) 88.2 (86.3–90.1) 48.2 (46.4–50.1) 56.9 (55.2–58.6)
K2Cr2O7 6.3 (4.9–8.2) 6.2 (5.0–7.7) 3.2 (2.4–4.2) 3.3 (2.5–4.4)
The effects of the ABCG2 inhibitor Ko143 are also shown. IC50 values were estimated with GraphPad Prism version 5 (95% conﬁdence interval).
Table 2
GSH content and activities of antioxidant enzymes in MDCKII and MDCKII-BCRP cells.
Cells GSH content
(nmol GSH/mg prot.)
Antioxidant enzyme
Glutathione S-transferase
(U/mg prot.)
Glutathione reductase
(U/mg prot.)
Glutathione peroxidase
(U/mg prot.)
MDCKII 113.8718.8 0.2070.07 0.5970.20 6.071.2
MDCKII-BCRP 71.875.3nn 0.1070.04nn 0.5170.13n 5.870.6ns
Data are presented as the mean 7 SD. Glutathione was estimated using o-phthalaldehyde and enzyme activities were estimated using spectrophotometric methods.
n p o 0.05 vs MDCKII cells.
nn p o 0.0001 vs MDCKII cells.
Fig. 2. The level of ROS estimated with dihydrorhodamine 123, 20 ,70-dichlorodihy-
droﬂuorescein diacetate, MitoSOX, and Amplex red in MDCKII and MDCKII-BCRP
cells. The cells were incubated at 37 1C for 15 min with 1 mM Amplex red, 1 mM
MitoSOX, 5 mM H2DCFDA, or 1 mM DHR123 and the ﬂuorescence of the products
was measured.
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intercellular concentration of total glutathione in the human
ﬁbroblast HEK293 cell line transfected with an HEK-ABCG2 vector
with respect to the same cells transfected with the pcDNA3.1
empty vector (10078 vs 130711 nmol glutathione/mg protein);
however, they found an increased rather than decreased level of
glutathione in ABCG2-transfected MCF-7 cells. Results of these
authors suggest, moreover, that ABCG2 does not transport glu-
tathione. Membrane vesicles of Sf9 insect cells, which were
infected with recombinant baculoviruses containing the cDNA of
wtABCG2 or ABCG2-K86M (inactive), showed no differences in
ATP-dependent [3H]methotrexate and [3H]GSH uptake. Also, no
signiﬁcant ATP-dependent ATP uptake by human erythrocyte
membrane vesicles (which contain ABCG2) was found. The
decrease in the glutathione level in ABCG2-overexpressing cells
should therefore be ascribed to a long-term modulation of cellular
glutathione level. ABCG2 is known to be regulated by various
signaling pathways including Nrf2, which is a critical transcrip-
tional factor regulating detoxiﬁcation enzymes and transporters
and, indirectly, glutathione content in response to oxidative stress.
That may show a link between ABCG2 expression and GSH
homeostasis [30].
In this study we demonstrate for the ﬁrst time that MDCKII-
BCRP cells show higher sensitivity to externally induced oxidative
stress from 24 h of incubation with paraquat, AAPH, hydrogen
peroxide, menadione, or tert-butylhydroperoxide.
The resistance of cells to oxidative stress may depend on many
factors, apart from the glutathione level. Previously, we examined
Chinese hamster V79 cells transfected with ABCC1 protein, which also
showed a decreased glutathione level but were not oversensitive to
oxidative stress-inducing agents compared to parental cells [31].
Therefore we estimated also the activities of main antioxidant
enzymes in the parental and transfected cells. The decreased glu-
tathione S-transferase and glutathione reductase activities may con-
tribute to the increased resistance of these cells to oxidative stress.
Glutathione S-transferase is involved in the conjugation of lipid
peroxidation products to glutathione and thus reduces their toxicity
[32,33], whereas lowered activity of glutathione reductase may make
the cells less efﬁcient in recycling glutathione oxidized under oxidative
stress conditions. The main reason for the increased vulnerability of
ABCG2-overexpressing MDCKII cells to oxidative stress, however,
seems to be the decreased glutathione level.
Shen at al. [34] claimed that the ABCG2 transporter reduces
ROS-mediated toxicity. They measured ROS levels using H2DCFDA
in the HEK293 control cell line and transfected with a plasmid
vector, pTT5SH8Q2, carrying a cDNA encoding human ABCG2, or
with an empty control vector pTT5SH8Q2, after incubation with
tert-butylhydroperoxide and hydrogen peroxide. They found
that cells overexpressing ABCG2 were more resistant to tBOOH
and H2O2 [34]. The reasons for this discrepancy are unclear but
may be related to the transfection efﬁciency, which was not at the
maximal level in the study of Shen et al., leading to lower
differences in the level of glutathione.
Our data suggest that increased sensitivity of MDCKII cells
overexpressing ABCG2 may be an example of collateral sensitivity
of multidrug-resistant cells. Similar results have been observed for
ABCB1-overexpressing cells (in preparation). These results point to
a potential possibility of using oxidant stress-generating agents
for eradication of cells overexpressing at least some multidrug
transporters.
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